Cargando…
PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer’s disease (AD). OBJECTIVE: We sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology. METHODS: We conducted a multi-center ob...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612013/ https://www.ncbi.nlm.nih.gov/pubmed/28800330 http://dx.doi.org/10.3233/JAD-170129 |
_version_ | 1783266045043146752 |
---|---|
author | Koychev, Ivan Gunn, Roger N. Firouzian, Azadeh Lawson, Jennifer Zamboni, Giovanna Ridha, Basil Sahakian, Barbara J. Rowe, James B. Thomas, Alan Rochester, Lynn Ffytche, Dominic Howard, Robert Zetterberg, Henrik MacKay, Clare Lovestone, Simon |
author_facet | Koychev, Ivan Gunn, Roger N. Firouzian, Azadeh Lawson, Jennifer Zamboni, Giovanna Ridha, Basil Sahakian, Barbara J. Rowe, James B. Thomas, Alan Rochester, Lynn Ffytche, Dominic Howard, Robert Zetterberg, Henrik MacKay, Clare Lovestone, Simon |
author_sort | Koychev, Ivan |
collection | PubMed |
description | BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer’s disease (AD). OBJECTIVE: We sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology. METHODS: We conducted a multi-center observational study in early AD (MMSE >20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of Aβ and tau at baseline and 6 months; PET-CT imaging with Aβ ([(18F)]AV45) and tau ([(18F)]AV1451) ligands at baseline. RESULTS: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants deteriorating faster despite lower levels of cortical tau. Cortical Aβ associated with entorhinal cortex tau while CSF tau/Aβ ratio correlated strongly with cortical tau but not Aβ. CONCLUSION: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker— the CSF total tau/Aβ ratio. |
format | Online Article Text |
id | pubmed-5612013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56120132017-10-02 PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers Koychev, Ivan Gunn, Roger N. Firouzian, Azadeh Lawson, Jennifer Zamboni, Giovanna Ridha, Basil Sahakian, Barbara J. Rowe, James B. Thomas, Alan Rochester, Lynn Ffytche, Dominic Howard, Robert Zetterberg, Henrik MacKay, Clare Lovestone, Simon J Alzheimers Dis Research Article BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer’s disease (AD). OBJECTIVE: We sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology. METHODS: We conducted a multi-center observational study in early AD (MMSE >20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of Aβ and tau at baseline and 6 months; PET-CT imaging with Aβ ([(18F)]AV45) and tau ([(18F)]AV1451) ligands at baseline. RESULTS: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants deteriorating faster despite lower levels of cortical tau. Cortical Aβ associated with entorhinal cortex tau while CSF tau/Aβ ratio correlated strongly with cortical tau but not Aβ. CONCLUSION: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker— the CSF total tau/Aβ ratio. IOS Press 2017-08-29 /pmc/articles/PMC5612013/ /pubmed/28800330 http://dx.doi.org/10.3233/JAD-170129 Text en © 2017 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Koychev, Ivan Gunn, Roger N. Firouzian, Azadeh Lawson, Jennifer Zamboni, Giovanna Ridha, Basil Sahakian, Barbara J. Rowe, James B. Thomas, Alan Rochester, Lynn Ffytche, Dominic Howard, Robert Zetterberg, Henrik MacKay, Clare Lovestone, Simon PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
title | PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
title_full | PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
title_fullStr | PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
title_full_unstemmed | PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
title_short | PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
title_sort | pet tau and amyloid-β burden in mild alzheimer’s disease: divergent relationship with age, cognition, and cerebrospinal fluid biomarkers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612013/ https://www.ncbi.nlm.nih.gov/pubmed/28800330 http://dx.doi.org/10.3233/JAD-170129 |
work_keys_str_mv | AT koychevivan pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT gunnrogern pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT firouzianazadeh pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT lawsonjennifer pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT zambonigiovanna pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT ridhabasil pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT sahakianbarbaraj pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT rowejamesb pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT thomasalan pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT rochesterlynn pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT ffytchedominic pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT howardrobert pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT zetterberghenrik pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT mackayclare pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT lovestonesimon pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers AT pettauandamyloidbburdeninmildalzheimersdiseasedivergentrelationshipwithagecognitionandcerebrospinalfluidbiomarkers |